Title	Expression of Grainyhead-like 2 in the Process of Ductal Development of Mouse Mammary Gland
Author(s)	Matsuoka, Shinya; Suzuki, Hiroyoshi; Kato, Chieko; Kamikawa-Tokai, Mai; Kamikawa, Akihiro; Okamatsu-Ogura, Yuko; Kimura, Kazuhiro
Citation	Journal of histochemistry and cytochemistry, 69(6), 373-388 https://doi.org/10.1369/00221554211013715
Issue Date	2021-06
Doc URL	http://hdl.handle.net/2115/82219
Rights	1. Matsuoka S, Suzuki H, Kato C, et al. Expression of Grainyhead-like 2 in the Process of Ductal Development of Mouse Mammary Gland. Journal of Histochemistry & Cytochemistry. 2021;69(6):373-388. doi:10.1369/00221554211013715
Type	article (author version)
File Information	jhc-Kimura-2020-00228R1-word.pdf

[Instructions for use](#)

Expression of grainyhead-like 2 in the process of ductal development of mouse mammary gland

Shinya Matsuoka, Hiroyoshi Suzuki, Chieko Kato, Mai Kamikawa-Tokai, Akihiro Kamikawa, Yuko Okamatu-Ogura, and Kazuhiro Kimura

Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan

Running head: Grhl2 in the mammary ductal development

Address for correspondence: Kazuhiro KIMURA, Ph.D.

Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18, Nishi9, Kita-ku, Sapporo 060-0818, Japan

Phone: +81-11-706-5204; Fax: +81-11-757-0703

E-mail: k-kimura@vetmed.hokudai.ac.jp

Abstract

Grainyhead-like 2 (Grhl2) is a transcription factor regulating cell adhesion genes. Grhl2 acts as an epithelial–mesenchymal transition (EMT) suppressor, and it is a proto-oncogene involved in estrogen-stimulated breast cancer proliferation. However, its expression during ovarian hormone-dependent mammary ductal development remains obscure. We here examined Grhl2 expression in the mammary gland of normal and steroid-replaced ovariectomized mice. Grhl2 protein signals were detected in both the mammary luminal and myoepithelial nuclei. The ratio and density of Grhl2-positive nuclei increased after the onset of puberty and progressed with age, whereas Grhl2-negative epithelial cells were detected in mature ducts. Claudin3, claudin4, claudin7, and E-cadherin gene expression in the mammary gland were upregulated, and their expression was highly correlated with Grhl2 gene expression. Furthermore, Grhl2 mRNA expression and ductal lumen width were significantly increased by the combined treatment of estrogen and progesterone compared with estrogen alone. These results suggest that Grhl2 expressed in the luminal and myoepithelium from the early phase of ductal development, controlling the expression of cell adhesion molecules to establish functional ducts.

Keywords: Claudin, E-cadherin, Estrogen, Grainyhead-like 2, Mammary gland, Ovariectomy, Postnatal development, Progesterone

Introduction

The mammary gland is a unique organ that primarily develops postnatally, and from ventral subcutaneous adipose tissue under the control of ovarian steroids. Newborn female mice possess quiescent rudimentary mammary ducts near their nipples that invade the surrounding stromal adipose tissue around 3–4 weeks of age and occupy the entire fat pad during puberty. The invading duct tips contain highly proliferative cell populations, and these structures are referred to as the terminal end buds (TEBs). They occasionally bifurcate into branch ducts to complete the ductal tree.^{1, 2} Moreover, some side branches sprout laterally from the main ducts, and additional side branches of a different character begin to develop in the luteal phase. These additional side branches become the milk-secreting acini during pregnancy and after delivery. The acinar structure recedes by extensive apoptosis after weaning, whereas the primary ductal structures remain in their pre-pregnant state.³⁻⁵

Tight junctions (TJs) are composed of several integral membrane proteins, including occludin and claudin (Cldn), as well as ~30 cytosolic molecules.⁶ In the mammary glands, TJs between adjacent secretory epithelial cells are formed during the period of lactogenesis and are instrumental in maintaining the difference between the basolateral side and the apical side of cells required for milk synthesis and secretion.⁷ Milk stasis by discontinued suckling

causes the alveolar size to increase and epithelial cells to flatten, followed by an increase in Cldn1 and Cldn3 protein expression and a decline in Cldn2 and Cldn16 protein expression.⁸ Furthermore, a study on claudin expression and localization in mammary gland development revealed that Cldn7 is present throughout development, Cldn3 is localized basolaterally to the TJ, and Cldn4 is found only in sparse puncta.⁹ In addition to the TJ, cadherins contribute to cell-cell contact and communication. E-cadherin as an adhesion receptor is critical for normal epithelial architecture development and may act as a tumor suppressor since its down-regulation in cancer cells induces phenotype alterations from epithelium to mesenchymal characteristics. This process is called the epithelial–mesenchymal transition (EMT) and leads to increase motility, invasiveness, and metastasis.¹⁰

Grainyhead-like 2 (Grhl2) is one of the three genes in a family of mammalian transcription factors related to *Drosophila Grainyhead*¹¹ and activates gene expression encoding epithelial cell adhesion molecules, such as E-cadherin and Cldn4.^{12, 13} Therefore, Grhl2 plays pivotal roles in epithelial barrier formation during kidney collecting duct development,¹⁴ placental trophoblast branching morphogenesis,¹⁵ as well as mucociliary airway epithelium establishment and maintenance.¹⁶ Additionally, Werner et al. have demonstrated Grhl2 has transforming activity as a proto-oncogene in breast cancer.¹⁷ Grhl2

can also act as an EMT suppressor molecule.^{13,17} Furthermore, Grhl2 is essential for estrogen-stimulated proliferation in estrogen receptor-positive (ER⁺) breast cancer cells.¹⁸

In postnatal mammary gland development, both stromal and epithelial ER α -mediated signals are required for ductal morphogenesis.¹⁹ Although Grhl2 is detected in the nucleus in normal breast epithelium adjacent to invasive ductal carcinoma,¹⁷ its regulation in postnatal mammary ductal development remains obscure. In the present study, we examined Grhl2 expression and function during mouse mammary ductal development and the possible reproductive hormone effect on its expression.

Materials and methods

Animal and tissue sampling

The experimental and animal care procedures were approved by the Animal Care and Use Committee of Hokkaido University (Hokkaido, Japan). All experiments using mice were performed in accordance with the guidelines of Hokkaido University Manual for Implementing Animal, in the animal facility approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. C57BL/6J female mice were purchased from Japan SLC Inc. (Shizuoka, Japan, $n=42$), housed in plastic cages in an air-conditioned room at 23°C with a 12:12 h light:dark cycle, and given free access to laboratory chow (Oriental Yeast, Tokyo, Japan). When applicable, the estrus cycle status was determined by vaginal smear analysis with Giemsa staining. Predominant detection of white cells in the smear was referred to as “time of estrus” and detection of the cornified epithelium was “time of non-estrus.”

To analyze *Grhl2* expression during postnatal development, 3-week-old ($n=6$), 7-week-old ($n=6$), and 17-week-old (both estrus and non-estrus $n=6$ each) female mice were used (total $n=24$). The mice were then euthanized, and the thoracic, abdominal, and inguinal mammary glands were quickly removed. Tissue samples were divided and transferred into

RNAlater storage solution (Thermo Fisher Scientific, Gaithersburg, MD, USA) for quantitative PCR analysis or 4% paraformaldehyde-containing phosphate-buffered solution (PB) for histological examination.

To examine the ovarian steroid effect on Grhl2 expression in the mammary gland, mice at 5 weeks of age were given an ovariectomy under anesthesia with a mixture of ketamine (75 mg/kg, Daiichi-Sankyo Propharma, Tokyo, Japan) and medetomidine (1 mg/kg, ZENOAQ, Fukushima, Japan). After the surgery, the mice received an intraperitoneal injection of antibiotics (ampicillin 5 mg/mouse, Meiji Seika, Tokyo, Japan) and a subcutaneous injection of atipamezole (1 mg/kg, ZENOAQ). After one week of the recovery period in term of body weight, the ovariectomized mice received a daily single subcutaneous injection of corn oil as a control (50 μ l, Co, $n=4$), estrogen (E, 1 μ g/50 μ l, Wako Pure Chemical, Osaka, Japan, $n=4$), progesterone (P, 1 mg/50 μ l, Wako, $n=5$), or both estrogen and progesterone (EP, 1 μ g E and 1 mg P/50 μ l, $n=5$), for 8 consecutive days (total $n=18$). Mammary glands were quickly excised 24 h after the last injection and stored in RNAlater solution or 4% paraformaldehyde containing PB.

Real-time PCR

Total RNA was extracted using RNAiso reagent (Takara Bio, Shiga, Japan) according

to the manufacturer's protocol. Then, mRNA was purified with a Dynabeads mRNA Purification kit (Life Technologies, Carlsbad, CA, USA) according to the protocol provided. The mRNA was reverse-transcribed using a 15-mer oligo(dT) adaptor primer and M-MLV reverse transcriptase (Promega, Madison, WI, USA). Real-time PCR was performed on a fluorescence thermal cycler (LightCycler system, Roche Diagnostics, Mannheim, Germany) using FastStart Essential DNA Green Master Mix (Roche Diagnostics). Absolute expression levels were determined using a standard curve method with cDNA fragments as standards. The mRNA levels are expressed as relative values compared to β -actin mRNA levels. The primers used in this study are listed in Table 1.

Histology

Tissue specimens were fixed in 4% paraformaldehyde containing PB, embedded in paraffin, and cut into 4 μ m thick sections that were stained with hematoxylin and eosin (HE). The stained samples were examined under a light microscope (objective magnification x4 or x20, Olympus BX50F, Olympus Optical Co., Tokyo, Japan). After taking photographs, the epithelial cell height and maximal lumen width of 24 ducts in each experimental group was measured (see also Fig. 5A).

Immunohistochemical staining of Grhl2 protein was performed on an antigen retrieval

section by heat treatment [105°C, 15 min in 10 mM citrate buffer (pH 6.0)]. The section was then sequentially incubated with 0.3% H₂O₂ for 20 min, 10% normal goat sera (Histofine SAB-PO(R) kit, Nichirei, Tokyo, Japan) for 1 h, and incubated with the anti-Grhl2 rabbit polyclonal antibody overnight (500X dilution at 4°C, HPA004820, Sigma-Aldrich Fine Chemical, St. Louis, MO, USA). Control incubation was performed in the absence of the primary antibody. Afterward, the section was incubated with a biotin-labeled secondary antibody for 1 h and peroxidase-conjugated streptavidin for 1 h (Histofine SAB-PO(R) kit), with extensive washing between incubations. Finally, the section was incubated with 3',3'-diaminobenzidine (DAB) solution for 10 min and hematoxylin for 10 sec. The stained samples were examined under a light microscope. The percentage of Grhl2 negative epithelial cells was assessed by counting all of the Grhl2 stained and non-stained ductal epithelial cells of 19 mammary ducts from each experimental group.

Immunofluorescence staining was performed using the anti-Grhl2 antibody (200X dilution) and anti- α -smooth muscle actin (α -SMA, a myoepithelium marker) mouse monoclonal antibody (200X dilution, A5228, Sigma) or Alexa Fluor 594 anti-CD324 (E-cadherin) rat monoclonal antibody (50X dilution, BioLegend, San Diego, CA, USA) in combination with Alexa Fluor 488-anti-rabbit IgG and 594-anti-mouse IgG antibodies

(A11008 and A11005, Invitrogen, Carlsbad, CA, USA), respectively. The nuclei were stained by 5 µg/ml Hoechst 33258 solution (Wako) for 1 h. Immunofluorescence staining was also performed by anti-Claudin 3 rabbit polyclonal antibody (100X dilution, 16456-1-AP, Proteintech, Rosemont, IL, USA), or anti-Claudin 4 rabbit polyclonal antibody (100X dilution, 16195-1-AP, Proteintech) with Alexa Fluor 594 anti-CD324 (E-cadherin) rat monoclonal antibody (50X dilution). Control incubation were performed in the absence of the primary antibodies.

Proliferating cell nuclear antigen (PCNA) and Ki-67 protein immunohistochemical staining was performed on an antigen retrieval section by 0.1% Triton X-100 for 1 h. The section was then sequentially incubated with 1% H₂O₂ for 15 min, 10% normal goat sera (Histofine SAB-PO(R) kit) for 30 min, and incubated using the anti-PCNA rabbit antibody (400X dilution at 4°C, sc-7907, Santa Cruz Biotechnology, CA, USA) or the anti-Ki-67 rabbit monoclonal antibody (200X dilution at 4°C, MA5-14520, Invitrogen) overnight. The section was then labeled using a biotin-labeled secondary antibody for 1 h and peroxidase-conjugated streptavidin for 1 h (Histofine SAB-PO(R) kit), with extensive washing between incubations. Finally, the section was incubated with DAB solution for 10 min. Control incubation were performed without primary antibodies.

Data analysis

The results are expressed as mean $\pm$ standard error (SE). Statistical analysis was performed by JMP Pro (14.0.0, SAS Institute Inc., Cary, NC, USA), using one-way analysis of variance (ANOVA) followed by a Tukey–Kramer post hoc test. The correlation between Grhl2 mRNA expression compared with Cldn3, Cldn4, or E-cadherin mRNA expression was evaluated by Pearson's correlation coefficient.

Results

Grhl2 mRNA and protein expression was examined in 3-week-old (around the onset of puberty), 7-week-old (puberty), and 17-week-old (adulthood) mouse mammary glands either at the time of estrus or non-estrus. Mice increased their body weight and mammary gland weight as a function of age (Figs. 1A and 1B). Grhl2 mRNA expression was increased 3- to 4-fold from 3 to 17 weeks (Fig. 1C). Grhl2 protein signals at 3 weeks of age were found in the nuclei, but the staining intensity was relatively weak compared with other age stages (Fig. 2A). In addition, non-stained epithelial nuclei (Fig. 2A, arrowheads in e and i) were observed in ~25% of the whole ductal epithelium (Figs. 2A and 2B). Grhl2 protein signals were increased and intensified at 7 weeks of age and were more densely expressed at 17 weeks irrespective of estrus cycle status. The number of non-stained epithelial nuclei decreased to ~5%. Immunofluorescence staining confirmed Grhl2-non-stained cells present in the duct luminal region and the TEB front region. Alpha-smooth muscle actin-positive myoepithelium also expressed Grhl2 (Fig. 2C).

To determine the molecular mechanism of Grhl2 mRNA and protein expression in the mammary gland, the ovarian steroid effect was examined in ovariectomized mice. Treatment of either estrogen or progesterone did not modify body weight or mammary gland weight,

while combined treatment of both steroids slightly increased body weight (Figs. 3A and 3B). Grhl2 mRNA expression in the mammary glands decreased (Fig. 3C) and the number of Grhl2-negative cells increased in response to estrogen treatment but not to progesterone treatment (Figs. 4A and 4B). In addition, relatively dispersed nuclei were observed in estrogen-treated mice (Fig. 4A), accompanied by an increase in luminal epithelial cell height (Fig. 5) and cell proliferation signals, PCNA and Ki-67 (Fig. 6). Compared to estrogen-treated mammary glands, EP combined treatment significantly increased and decreased Grhl2 mRNA expression and the number of Grhl2-negative cells (Fig. 3C and Fig. 4). The ductal lumen width was also increased by the combined treatment compared with estrogen alone (Fig. 5B).

To reveal the relationship between Grhl2 expression and gene expression of cell adhesion molecules in mammary glands, Cldn1, Cldn2, Cldn3, Cldn4, Cldn7, Cldn9, and E-cadherin gene expression were examined. Among these, expression of Cldn2 and Cldn9 were relatively lower than the other Cldn tested. Since Cldn2 mRNA levels in almost the half samples were less than detection limit (data not shown), thus we excluded data of Cldn2 from analysis. Expression of Cldn3, Cldn4, Cldn7, and E-cadherin genes were increased age-dependently like Grhl2 expression, while expression of Cldn1 and Cldn9 were decreased with age (Fig.1C and Fig.7). In addition, expression of claudin family genes and E-cadherin was

examined in ovariectomized mice. Expression of Cldn1 was significantly decreased by either estrogen or progesterone treatments, and similar decrease was observed by EP combined treatment (Fig. 8A). The other Cldn expression was not influenced by estrogen and progesterone alone, although EP combined treatment increased Cldn3, Cldn7, and Cldn9 expression significantly (Figs. 8B, 8D, and 8E). A similar trend was found with Cldn4 and E-cadherin expression (Figs. 8C and 8F). Furthermore, high positive correlations between Grhl2 mRNA expression and respective mRNA expression of Cldn3, Cldn4, Cldn7, and E-cadherin genes were observed, although expression of Cldn1 and Cldn9 did not correlate with expression of Grhl2 (Fig. 9 and Table 2). When the data of postnatal development and of steroid treatments in Cldn4, Cldn7, and E-cadherin separately were analyzed, the slopes of regression lines were almost identical between these two data. However, in case of Cldn3, the steroid treatment has steep slope of linear regression, compared to postnatal development.

Finally, double staining was performed to confirm co-localization of Grhl2 and E-cadherin in the mouse mammary gland. As expected, mammary ductal epithelial cells expressed both E-cadherin and Grhl2 (Fig.10). Moreover, Cldn3 signal was present on the plasma membrane of ductal cells where E-cadherin was expressed (Fig.11). Cldn4 signal was found in the mammary duct at 4 to 8 weeks of age, but not in 15 weeks of age (Fig.12).

Discussion

In the present study, we have demonstrated that Grhl2 mRNA and protein expression in mouse mammary ductal epithelium is detected as early as 3 weeks of age, but signals in one-fourth of the ductal epithelium are negative. Furthermore, Grhl2 mRNA and protein expression increased at puberty and thereafter, suggesting that increased estrogen after the onset of puberty is involved in regulating Grhl2 gene expression. Although normal and tumor ER signals are distinct, Grhl2 acts as an ER-cooperating tumorigenic transcription factor.¹⁸ As phosphorylated ER sites, unlike ER sites, are enriched in Grhl2 DNA-binding motifs, and estrogen treatment increases Grhl2 recruitment to former sites in MCF-7 cells.²⁰ However, estrogen treatment alone tended to decrease Grhl2 and its target gene expression in ovariectomized mice, indicating that estrogen is unlikely to induce Grhl2 transcription and activation in the normal ductal epithelial cells.

Estrogen caused cell proliferation, increased luminal cell width, and increased the Grhl2-negative cell number. They existed in the duct luminal region and the TEB front region. In the former, Grhl2-negative cells look like normal cells just after asymmetric division, which lose their polarity as described by Huebner and Ewald.² In addition, TEB is composed of internal low-polarity cells having a loose cell–cell contact without TJs.² Therefore, it is

suggested that Grhl2 expression is inversely regulated to estrogen-dependent cell proliferation during ductal development.

It is reported that progesterone receptor signals are critical for mature mammary gland side branching and lobuloalveolar development.^{21, 22} However, treatment of progesterone alone in ovariectomized mice did not alter any parameters tested, except decrease in Cldn1 expression. The combined treatment of EP increased Grhl2 expression when compared with estrogen treatment. This supports the view that estrogen signals in cooperation with progesterone signals govern mammary gland development in adult mice.¹⁹ This increase in Grhl2 was accompanied by enhanced Cldn3 and Cldn7 expression and ductal lumen width enlargement. As the steroid doses used were expected to mimic physiological circulating concentrations of pregnant mice,²³ a duct with a functional TJ might be formed by these hormones, as was the case for late pregnancy and early lactational stages.

Grhl2 expression was proportionally expressed with Cldn3, Cldn4, Cldn7, and Cdh1 (E-cadherin). Cldn4 and E-cadherin are direct targets of the Grhl2 transcription factor^{12, 13} and the Grhl2 gene is the most tightly correlated with E-cadherin expression in some cancer cells.²⁴ We also observed an extremely high correlation between Grhl2 and E-cadherin mRNA expression. As seen in Fig.10, many of ductal epithelium expressing Grhl2 expressed E-

cadherin, resulting in solid duct formation. The correlation analysis also revealed that Cldn3 expression was enhanced by the EP combination compared with normal ductal development, while Cldn4 and Cldn7 expression was regulated in a uniform way like E-cadherin. These results support the findings that each Cldn expression are regulated independently through mammary gland development,⁹ although difference in the mechanism of postnatal and steroid-induced Grhl2-dependent Cldn3 expression needs to be clarified.

In summary, we have found the EMT suppressor, Grhl2 is expressed in the nuclei of luminal epithelium and myoepithelium as early as the onset of puberty. This causes the expression of EMT suppressor molecules, such as E-cadherin, Cldn3, Cldn4, and Cldn7. Steroid replacement studies in ovariectomized mice suggest that estrogen indirectly suppresses Grhl2 expression and increases cell proliferation. These data suggest that Grhl2-non-stained cells in the mammary duct in adult mice might express low levels of EMT suppressors and might be vulnerable to internal and external stimuli leading to side branching and lobuloalveolar development after pregnancy or during tumorigenesis.

Competing interest

The authors declare they have no competing interests

Funding

This work was supported by KAKENHI grant (19H03116 to K. Kimura).

Author contributions

KK designed experiments. SM, HS, CK, and MK-T performed experiments. AK and YO-O provided experimental support and intellectual input. KK and SM wrote the manuscript. All authors have read and approved the final manuscript.

References

1. Fendrick JL, Raafat, AM, Haslam SZ. Mammary gland growth and development from the postnatal period to postmenopausal: ovarian steroid receptor ontogeny and regulation in the mouse. *J Mammary Gland Biol Neoplasia*. 1998;3:7–22.
2. Huebner RJ, Ewald AJ. Cellular foundations of mammary tubulogenesis. *Semin Cell Dev Biol*. 2014;31:124–31.
3. Lund LR, Rømer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Danø K, Werb Z. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. *Development*. 1996;122:181–93.
4. Hinck L, Silberstein GB. Key stages in mammary gland development. The mammary end bud as a motile organ. *Breast Cancer Res*. 2005;7:245–51. Doi: 10.1186/bcr1331.
5. Lanigan F, O'Connor D, Martin F, Gallagher WM. Molecular links between mammary gland development and breast cancer. *Cell Mol Life Sci*. 2007;64:3159–84.
6. Itoh M, Bissell MJ. The organization of tight junctions in epithelia: Implications for mammary gland biology and breast tumorigenesis. *J Mammary Gland Biol Neoplasia*. 2003;8:449–62.
7. Stelwagen K, Singh K. The role of tight junctions in mammary gland function. *J*

- Mammary Gland Biol Neoplasia. 2014;19:131–38.
8. Markov AG, Kruglova NM, Fomina YA, Fromm M, Amasheh S. Altered expression of tight junction proteins in mammary epithelium after discontinued suckling in mice. Pflugers Arch. 2012;463:391–98. doi: 10.1007/s00424-011-1034-2.
 9. Baumgartner HK, Rudolph MC, Ramanathan P, Burns V, Webb P, Bitler BG, Stein T, Kobayashi K, Neville MC. Developmental expression of claudins in the mammary gland. J Mammary Gland Biol Neoplasia. 2017;22:141–57. doi: 10.1007/s10911-017-9379-6.
 10. Andrews JL, Kim AC, Hens JR. The role and function of cadherins in the mammary gland. Breast Cancer Res. 2012;14:203.
 11. Harrison MM, Botchan MR, Cline TW. Grainyhead and Zelda compete for binding to the promoters of the earliest-expressed *Drosophila* genes. Dev Biol. 2010;345:248–55.
 12. Werth M, Walentin K, Aue A, Schönheit J, Wuebken A, Pode-Shakked N, Vilianovitch L, Erdmann B, Dekel B, Bader M, Barasch J, Rosenbauer F, Luft FC, Schmidt-Ott KM. The transcription factor grainyhead-like 2 regulates the molecular composition of the epithelial apical junctional complex. Development. 2010 137(22):3835–45. doi: 10.1242/dev.055483.
 13. Frisch SM, Farris JC, Pifer PM. Roles of Grainyhead-like transcription factors in cancer.

- Oncogene. 2017;36:6067–73.
14. Aue A, Hinze C, Walentin K, Ruffert J, Yurtdas Y, Werth M, Chen W, Rabien A, Kilic E, Schulzke J-D, Schumann M, Schmidt-Ott KM. A Grainyhead-like 2/Ovo-like 2 pathway regulates renal epithelial barrier function and lumen expansion. *J Am Soc Nephrol.* 2015;26:2704–15.
 15. Walentin K, Hinze C, Werth M, Haase N, Varma S, Morell R, Aue A, Pötschke E, Warburton D, Qiu A, Barasch J, Purfürst B, Dieterich C, Popova E, Bader M, Dechend R, Staff AC, Yurtdas ZY, Kilic E, Schmidt-Ott KM. A Grhl2-dependent gene network controls trophoblast branching morphogenesis. *Development.* 2015;142:1125–36. doi:10.1242/dev.113829
 16. Gao X, Vockley CM, Pauli F, Newberry KM, Xue Y, Randell SH, Reddy TE, Hogan BL. Evidence for multiple roles for grainyhead-like 2 in the establishment and maintenance of human mucociliary airway epithelium. *Proc Natl Acad Sci USA* 2013;110:9356–61.
 17. Werner S, Frey S, Riethdorf S, Schulze C, Alawi M, Kling L, Vafaizadeh V, Sauter G, Terracciano L, Schumacher U, Pantel K, Assmann V. Dual roles of the transcription factor Grainyhead-like 2 (GRHL2) in breast cancer. *J Biol Chem.* 2013;288:22993–3008.
 18. Chi D, Singhal H, Li L, Xiao T, Liu W, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao

- P, Long H, Garber J, Brown M. Estrogen receptor signaling is reprogrammed during breast tumorigenesis. *Proc. Natl. Acad. Sci. USA* 2019;116:11437–43.
19. Mueller SO, Clark JA, Myers PH, Korach KS. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor α . *Endocrinology* 2002;143:2357–65.
 20. Helzer, KT, Szatkowski Ozers M, Meyer MB, Benkusky NA, Solodin N, Reese RM, Warren CL, Pike JW, Alarid ET. The phosphorylated estrogen receptor α (ER) cistrome identifies a subset of active enhancers enriched for direct ER-DNA binding and the transcription factor GRHL2. *Mol. Cell. Biol.* 2019;39:e00417–18.
 21. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes Dev.* 1995;9:2266–78.
 22. Humphreys RC, Lydon J, O'Malley BW, Rosen JM. Mammary gland development is mediated by both stromal and epithelial progesterone receptors. *Mol Endocrinol.* 1997;11:801–11.
 23. McCormack JT, Greenwald GS. Progesterone and oestradiol-17 β concentrations in the peripheral plasma during pregnancy in the mouse. *J Endocrinol.* 1974;62:101–7.

24. Kohn KW, Zeeberg BM, Reinhold WC, Pommier Y. Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. PLoS One 2014;9:e99269.

Figure legends

Figure 1. Changes in body weight, thoracic mammary gland weight, and Grhl2 mRNA expression during postnatal development in normal mice. Mice were sacrificed at 3 ($n=6$), 7 ($n=6$), and 17 weeks ($n=12$) of age. The body weight (A) and the thoracic mammary gland weight (B) were measured. Grhl2 gene expression in the abdominal mammary gland was determined by real-time PCR (C). Data for 17-week-old mice were analyzed depending on their estrus cycle status; 17E was in the time of estrus ($n=6$), while 17NE was in the time of non-estrus ($n=6$). *, $P < 0.05$ vs. 3 weeks of age.

Figure 2. Grhl2 protein expression during postnatal development in normal mice.

Mice were sacrificed as described in the Fig. 1 legend. In panel A, the first row (a, e, i) is from 3-week-old mice; the second row (b, f, j) is from 7-week-old mice; the third row (c, g, k) is from 17E; and the fourth row (d, h, l) is from 17 NE. Arrowheads indicate the luminal epithelium not stained by the anti-Grhl2 antibody. In i to l, the insert shows the magnified image of the boxed region. In (B), the Grhl2 negative mammary epithelial cell percentage per total ductal epithelial cells was calculated by counting the cell number in 19 ducts from 6 mice in each age group. Tissue specimen from 7-week-old mice were also stained with both

anti-Grhl2 (green) and anti- α -SMA (red, a marker of myoepithelium) in (C). Arrows indicate the myoepithelium Grhl2-expressing nuclei, while arrowheads show luminal epithelium not stained with anti-Grhl2. The scale bar in rows a to d in (A) indicates 500 μ m, while the scale bar in rows e to l of (A) and (C) is 50 μ m. *, $P < 0.05$ vs. 3 weeks of age.

Figure 3. The ovarian steroid effect on body weight, thoracic mammary gland weight, and Grhl2 mRNA expression in ovariectomized mice mammary glands. Ovariectomized mice at 6 weeks of age received single daily subcutaneous injections of corn oil as a control solvent (Co, $n=4$), estrogen (E, $n=4$), progesterone (P, $n=5$), or both estrogen and progesterone (EP, $n=5$) for 8 consecutive days. Mice were sacrificed at 24 h after the last injection. Body weight (A) and the thoracic mammary gland weight (B) were measured. Grhl2 mRNA expression in the abdominal mammary gland was quantified by real-time PCR (C). *, $P < 0.05$ vs. control. †, $P < 0.05$ vs. E injection.

Figure 4. The ovarian steroid effect on Grhl2 protein expression in ovariectomized mice mammary glands. Mice were treated as described in the Fig. 3 legend. In panel A, the first row (a, e, i) is corn oil (C, $n=4$); the second row (b, f, j) is estrogen (E, $n=4$); the third row (c,

g, k) is progesterone (P, $n=5$); and the fourth row (d, h, l) is both estrogen and progesterone (EP, $n=5$). Arrowheads indicate the luminal epithelium not stained by the antibody. In I to l, the insert shows magnified images of the boxed region. In (B), the Grhl2 negative mammary epithelial cell percentage per total ductal epithelial cells was calculated by the cell number counted 19 ducts of 4-5 mice in each experimental group. †, $P < 0.05$ vs. E injection. The scale bar in a to d indicates 500 μm while it in e to l 50 μm .

Figure 5. The ovarian steroid effect on the ductal epithelial layer and ductal lumen

width in ovariectomized mice mammary glands. Ovariectomized mice were treated with corn oil (Co), estrogen (E), progesterone (P), or both estrogen and progesterone (EP). HE stained mammary gland sections were prepared. The epithelial layer and lumen widths of 24 ducts from 3 mice in each group were measured as shown in (A). The lumen width and epithelial width (height) averages are summarized in (B) and (C), respectively. *, $P < 0.05$ vs. Control (Co). †, $P < 0.05$ vs. E injection. The scale bar indicates 50 μm .

Figure 6. The ovarian steroid effect on ductal epithelial cell proliferation in

ovariectomized mice mammary glands. Ovariectomized mice were treated with corn oil

(Co), estrogen (E), progesterone (P), or both (EP), as described in legend of figure 3. PCNA and Ki-67 expression, cell proliferation markers, were determined by immunohistochemistry. Typical Ki-67 staining of ductal cells are shown in (A). The ratio of PCNA (B) and Ki-67(C) positive mammary epithelial cell to total ductal epithelial cells was calculated by the number of epithelial cells of 20-24 ducts from 3 mice for PCNA and 30 ducts from 3 mice for Ki-67. *, $P < 0.05$ vs. Control (Co), †, $P < 0.05$ vs. E injection. The scale bar indicates 50 μm .

Figure 7. Claudin family and E-cadherin mRNA expression mouse mammary glands

during postnatal development. Cldn1 (A), Cldn3 (B), Cldn4 (C), Cldn7 (D), Cldn9 (E), and E-cadherin (F) mRNA expression was determined by real-time PCR on the same samples prepared in Fig. 1C ($n=6$ each). *, $P < 0.05$ vs. 3 weeks of age

Figure 8. The ovarian steroid effect on ovariectomized mice mammary gland Cldn

family and E-cadherin mRNA expression. Cldn1 (A), Cldn3 (B), Cldn4 (C), Cldn7 (D), Cldn9 (E), and E-cadherin (F) mRNA expression was determined by real-time PCR on the same samples prepared in Fig. 3C ($n=4$ or 5). *, $P < 0.05$ vs. Control (Co), †, $P < 0.05$ vs. E injection.

Figure 9. Correlation between Grhl2 mRNA expression and mRNA expression of the cell adhesion molecules. Correlation between Grhl2 mRNA expression and Cldn1 (A), Cldn3 (B), Cldn4 (C), Cldn7 (D), Cldn9 (E), and E-cadherin (F) mRNA expression was analyzed. Closed circle indicates data from the postnatal development with a solid regression line ($n=24$). The cross symbol indicates data from the steroid treatment with a dotted regression line ($n=16$ or 18). The respective correlation coefficients were summarized in Table 2.

Figure 10. Expression of Grhl2 and E-cadherin protein during postnatal development in normal mice. Mice were sacrificed at 4, 8, and 15 weeks ($n=2$ each). Specimens were stained with both anti-Grhl2 (green) and anti-E-cadherin (red). Arrows indicate the Grhl2-negative cells. The scale bar indicates 50 μm .

Figure 11. Expression of claudin3 protein along with during postnatal development in normal mice. Mice were sacrificed at 4, 8, and 15 weeks ($n=2$ each). Specimens were stained with anti-cldn3 (green), along with E-cadherin (red). The scale bar indicates 50 μm .

Figure 12. Expression of claudin4 protein along with during postnatal development in normal mice. Mice were sacrificed at 4, 8, and 15 weeks ($n=2$ each). Specimens were stained with anti-cldn4 (green), along with E-cadherin (red). The scale bar indicates 50 μm .

Table legends

Table 1. Primer list used in this paper.

Table 2. Correlation between Grhl2 and cell adhesion molecules mRNA expression

Table 1. Primers used.

Target genes	Primer sequences
<i>Actb</i> (β -actin)	F: 5'-AAG TGT GAC GTT GAC ATC CG-3' R: 5'-GAT CCA CAC AGA GTA CTT GC-3'
<i>Grhl2</i>	F: 5'-ACA GCC AAG AAG ACC AGG AT-3' R: 5'-GAT GGA TAC ACT GTA CTG CT-3'
<i>Cldn1</i>	F: 5'-TTC AGG TCT GGC GAC ATT AG -3' R: 5'-AAG AGG GCC TGG CCA AAT TC -3'
<i>Cldn2</i>	F: 5'-AGA GCT CTT CGA AAG GAC GG -3' R: 5'-AGG ATG TAG CCC ACC AGT TG -3'
<i>Cldn3</i>	F: 5'-TCG GCC AAC ACC ATC ATC AG-3' R: 5'-CAG AAT AGA GGA TCT TGG TG-3'
<i>Cldn4</i>	F: 5'-TCA TCC TGA GTT GTG CGC TC-3' R: 5'-TGA TGC TGA TGA CCA TAA GG-3'
<i>Cldn7</i>	F: 5'-AAT GTA CGA CTC GGT GCT CG -3' R: 5'-TTC GGG CCT TCT TCG CTT TG-3'
<i>Cldn9</i>	F: 5'-CTG CGA AGC TCA CTT ATT GG -3' R: 5'-CCA GAG TAA GAA AGT CCA GG-3'
<i>Cdh1</i> (E-cadherin)	F: 5'-TCA GTT CCG AGG TCT ACA CC-3' R: 5'-GAT GCC GCT TCA CTG TGA TG-3'

1

¹ Abbreviation: F, Forward primer. R, Reverse primer. Cldn, claudin.

Table 2. Correlation between Grhl2 and cell adhesion molecules mRNA expression

	Cldn1	Cldn3	Cldn4	Cldn7	Cldn9	E-cadherin
Development	-0.07	0.77**	0.61**	0.81**	-0.36	0.94**
<i>Mouse</i>	24	24	24	24	24	24
OVX+steroid	0.18	0.77**	0.77**	0.54*	0.25	0.89**
<i>Mouse</i>	18	18	18	18	16	18
Total	-0.08	0.61**	0.67**	0.69**	-0.29	0.91**
<i>Mouse</i>	42	42	42	42	40	42

²

² Abbreviation: OVX, ovariectomy. *: $P < 0.05$, **: $P < 0.01$

A **B** **C**

A Age (weeks)

B

C

A **B** **C**

A

B

A

B

C

A

B

C